VISEN Pharmaceuticals (02561) published a monthly return on equity movements for the period ended 31 January 2026. The authorised share capital remained unchanged at 500,000,000 ordinary shares, each with a par value of USD 0.0001, for a total of USD 50,000. The number of issued shares stayed at 113,926,864, and there were no treasury shares at the end of January 2026.

No changes were reported under share options, warrants, convertibles, or any other arrangements to issue shares. Under the Post-IPO Share Award Scheme, there were no new issuances during the month, leaving the total number of shares unchanged. The public float requirement, set at 25% of issued shares excluding treasury shares, remained in compliance.